PharmaCyte Biotech, Inc. (PMCB)
NASDAQ: PMCB · Real-Time Price · USD
1.740
-0.090 (-4.92%)
Nov 4, 2024, 4:00 PM EST - Market closed

PharmaCyte Biotech Cash Flow Statement

Millions USD. Fiscal year is May - Apr.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Jul '24 Apr '24 Apr '23 Apr '22 Apr '21 Apr '20 2019 - 2015
Net Income
26.940.33-4.32-4.24-3.55-3.83
Upgrade
Asset Writedown & Restructuring Costs
22----
Upgrade
Loss (Gain) From Sale of Investments
-20.551.57----
Upgrade
Stock-Based Compensation
0.90.670.650.110.441.22
Upgrade
Other Operating Activities
-11.95-7.030.17--0.08-
Upgrade
Change in Accounts Payable
-0.160.26-0.240.03-0.010.06
Upgrade
Change in Other Net Operating Assets
-0.040.04-0.05-0.02-0.130.2
Upgrade
Operating Cash Flow
-2.87-2.15-3.79-4.12-3.33-2.34
Upgrade
Other Investing Activities
-5-5----
Upgrade
Investing Cash Flow
-12-5----
Upgrade
Long-Term Debt Issued
-----0.08
Upgrade
Total Debt Issued
-----0.08
Upgrade
Long-Term Debt Repaid
----0.05-0.06-0.01
Upgrade
Total Debt Repaid
----0.05-0.06-0.01
Upgrade
Net Debt Issued (Repaid)
----0.05-0.060.06
Upgrade
Issuance of Common Stock
-0087.364.72.66
Upgrade
Repurchase of Common Stock
-2.48-28.2-13.56---
Upgrade
Financing Cash Flow
-27.16-10.71-13.5687.314.642.73
Upgrade
Foreign Exchange Rate Adjustments
-0-0-0.0100-0.01
Upgrade
Net Cash Flow
-42.03-17.86-17.3683.21.310.38
Upgrade
Free Cash Flow
-2.87-2.15-3.79-4.12-3.33-2.34
Upgrade
Free Cash Flow Per Share
-0.34-0.22-0.19-0.27-2.30-2.59
Upgrade
Cash Interest Paid
---000
Upgrade
Cash Income Tax Paid
-0-000
Upgrade
Levered Free Cash Flow
3.13-2.55-3.52-2.62-1.97-1.03
Upgrade
Unlevered Free Cash Flow
3.13-2.55-3.52-2.62-1.97-1.03
Upgrade
Change in Net Working Capital
-5.8-0.850.13-0.010.15-0.14
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.